Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.
about
Bisphosphonates and other bone agents for breast cancerBisphosphonates for breast cancerThe present and future role of bisphosphonates in the management of patients with breast cancer.Biology of bone metastases.Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myelomaPercutaneous radiofrequency ablation of painful osseous metastases: a multicenter American College of Radiology Imaging Network trialBisphosphonates for the relief of pain secondary to bone metastases.Tolerability of intravenous pamidronate for the treatment of osteoporosis and other metabolic osteopathies: A retrospective analysis.Use of intravenous bisphosphonates in older women with breast cancerBisphosphonates: from grandparents to grandchildren.Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases.The neurological safety of epidural pamidronate in ratsRecent developments in bisphosphonates for patients with metastatic breast cancer.The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases.Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies.Malignant bone pain: pathophysiology and treatments.Use of bisphosphonates in skeletal metastasis.Clinical course and prognostic factors following bone recurrence from breast cancer.Using bisphosphonates to control the pain of bone metastases: evidence-based guidelines for palliative care.Emerging therapies in metastatic bone pain.The application of genomic and molecular data in the treatment of chronic cancer pain.Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasisBone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian GuidelineBone-Targeted Agents for the Management of Breast Cancer Patients with Bone MetastasesChemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?Treatment of Bone Metastases in Patients with Advanced Breast Cancer.Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.Bisphosphonates in breast cancer.A primer of bone metastases management in breast cancer patients.The role of the bone microenvironment in skeletal metastasis.'Who', 'when' and 'how' in re-irradiation of recurrent painful bone metastases.Zoledronic acid in the management of metastatic bone disease.Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trial.Pharmacotherapy of bone metastases in breast cancer patients.Bisphosphonate-induced Severe Hypocalcemia - A Case Report -.Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trialInterdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012.Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy.Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: A systematic review within the European Association for Palliative Care guidelines project.Bisphosphonates: are they standard of care for the treatment of breast cancer?
P2860
Q24203656-D506B183-8E9E-4C23-96BE-4EE547B16A51Q24246519-4D691DCD-F09B-426C-8EA4-BF981471D7D6Q24802100-4C05F28D-52C3-4A98-9678-38708405E62AQ27693653-49C02C53-9F0A-4C08-B075-F8E33FA73BF0Q28081996-D2C70DFB-4C00-477F-AB2D-788CA7071C19Q28269037-A00839DD-BC96-4B7A-BADB-4BF29BF53F92Q32139406-111F7DA0-6368-4900-8328-2F85257B69D2Q33414289-FDCA7899-D25D-49AF-AEF0-EBEECDAEF6CCQ33666930-F3F32FD1-B714-40E9-AEA6-E7EF459D9C0DQ33807859-364FD800-043B-4D7B-AEF8-E03CB24D98A1Q33909847-FFF09CCC-C32F-4EF7-A181-5AEF5A5BB5DBQ33915687-2F5C0390-1F71-4696-AC66-824D1842D4BBQ33935632-20BEBDA2-3DCA-4A42-8FA9-5CD6A96B9B3CQ33970557-D56B42E2-2586-4F77-9AEB-C324DDE4E013Q33970595-C8F2BED5-ED8C-4EB9-9E11-9FEE38F60D53Q34040552-EC60F124-2603-481D-AA24-F47069CAE416Q34065811-C66CB30F-B09F-458F-AF94-8B9DECFFB1F3Q34065927-6720775B-0518-4BC7-9E1F-156069A94AABQ34162842-09D685F5-B586-499A-90F5-07B348B0B0F5Q34182919-F4358A98-F03E-4F10-9D98-667B0F41B3E3Q34207230-D9944790-9173-4FCD-99C3-EFC1E3C3907CQ35345620-456019B6-44D0-4999-982A-C925B1E5E229Q35750472-12386607-AEEA-4AEB-A00D-7C6EFD3BDD5FQ35750641-EC5B4936-C16E-4081-9D47-3C62EFB41E46Q35815486-EEF3A08E-2243-4147-9E50-11012315E1ECQ36036088-BE396E47-1657-4E5A-B527-8D8D480A8615Q36080739-56061947-B3AE-479A-BDEF-080DC1249255Q36085307-4A231F26-42AF-4899-9AEB-265C14F07A06Q36410656-F54EF097-A00C-4EB9-9E7C-9A2AB7FAC0C1Q36491430-D227C4F3-5C09-403D-843E-781A577E9517Q36491439-D6FF8D97-9CFC-45D3-91F9-4523AE025C74Q36708315-56673263-7FBF-4B96-88AF-5D6CC51F4A66Q37094993-61B913CF-EF6A-428D-95FC-6F180340A51DQ37123398-E16D9819-4C45-4738-B5A2-D5D61FEB347CQ37192055-D234BAD9-FAD3-458B-AF9B-77BE6DFE074BQ37435405-5EB158AD-EF56-487C-A070-3270A24B9A34Q37657782-C9CA70FF-9BDA-4CBC-A230-97E4584EDE07Q38581768-CD975AD8-B273-4D0F-8C6E-9D9BDCB7984EQ38785899-FF189662-E0DE-460A-B53A-DBFA12784CC2Q43199020-CDF5DB5F-F3B5-40DC-A739-BC03E8C02941
P2860
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Delay in progression of bone m ...... ltinational Cooperative Group.
@en
Delay in progression of bone m ...... ltinational Cooperative Group.
@nl
type
label
Delay in progression of bone m ...... ltinational Cooperative Group.
@en
Delay in progression of bone m ...... ltinational Cooperative Group.
@nl
prefLabel
Delay in progression of bone m ...... ltinational Cooperative Group.
@en
Delay in progression of bone m ...... ltinational Cooperative Group.
@nl
P2093
P1476
Delay in progression of bone m ...... ultinational Cooperative Group
@en
P2093
F Calabresi
G Francini
J Bonneterre
J Latreille
P304
P356
10.1200/JCO.1996.14.9.2552
P407
P577
1996-09-01T00:00:00Z